Tumor Biology

, Volume 37, Issue 4, pp 5485–5492 | Cite as

Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study

  • Ming-zhu Yin
  • Shu Tan
  • Xia Li
  • Yan Hou
  • Guosheng Cao
  • Kang Li
  • Junping Kou
  • Ge Lou
Original Article


Metabolites are the end products of cellular regulatory processes. Squamous cervical cancer (SCC) can alter the level of certain small molecular metabolite in plasma through modulating gene expression. In this study, we identified two metabolites, phosphatidylcholine (PC) and lysophosphatidylcholine (LPC), which are significantly down- and upregulated in plasma of SCC as compared to uterine fibroid (UF) patients via ultra-performance liquid chromatographic-mass spectrometry (UPLC-MS). In external prospective cohort, our assay has a sensitivity of 93.2 %, a specificity of 91.3 %, and an area under the receiver operating characteristic (ROC) curve (AUC) of 0.972. The level of LPC is significantly higher in SCC than in UF patients. An opposite result was observed in PC level. Our findings suggest that the PC and lysoPC could be used as novel biomarkers to facilitate SCC diagnosis.


Metabonomics Cervical cancer Phosphatidylcholine Lysophosphatidylcholine Biomarker 



The study was supported by a grant from the National Natural Science Foundation of China (NSFC 81172453) and the Tumor Hospital of Harbin Medical University Starting Foundation (JJZ2011-08), and the present research was supported by the National Natural Science Foundation of China (No. 81274131), 2011 Program for Excellent Scientific and Technological Innovation Team of Jiangsu Higher Education, a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Project Program of the State Key Laboratory of Natural Medicines, China Pharmaceutical University (No. JKGZ201107).

Compliance with ethical standards

Procedures used in this study were approved by the ethics committee of the Tumor Hospital of Harbin Medical University.

Consent to participate

All subjects signed the consent form and agreed to have their plasma samples used for scientific purposes.

Conflicts of interest



  1. 1.
    Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11):1181–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Fiehn O. Metabolomics—the link between genotypes and phenotypes. Plant Mol Biol. 2002;48:155–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Welthagen W, Shellie R, Ristow M, Spranger J, Zimmermann R, Fiehn O. Comprehensive two dimensional gas chromatography-time of flight mass spectrometry, GCxGC-TOF for high resolution metabolomics: biomarker discovery on spleen tissue extracts of obese NZO compared to lean C57BL/6 mice. Metabolomics. 2005;1:57–65.CrossRefGoogle Scholar
  4. 4.
    Wang X, Sun H, Zhang A, Wang P, Han Y. Ultra-performance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies. J Sep Sci. 2011;34(24):3451–9. Review.CrossRefPubMedGoogle Scholar
  5. 5.
    Gouveia MJ, Brindley PJ, Santos LL, da Costa JM C, Gomes P, Vale N. Mass spectrometry techniques in the survey of steroid metabolites as potential disease biomarkers: a review. Metabolism. 2013;62(9):1206–17.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Odunsi K, Wollman RM, Ambrosome CB, Hutson A, McCann SE, Tammela J, et al. Detection of epithelial ovarian cancer using H-1-NMR-based metabonomics. Int J Cancer. 2005;113:782–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res. 2010;16(23):5835–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Abate-Shen C, Shen MM. Diagnostics. The prostate-cancer metabolome. Nature. 2009;457(7231):799–800.CrossRefPubMedGoogle Scholar
  9. 9.
    Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res. 2010;9(6):2988–95.CrossRefPubMedGoogle Scholar
  10. 10.
    Zhang T, Wu X, Ke C, Yin M, Li Z, Fan L, et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res. 2013;12(1):505–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Hou Y, Yin M, Sun F, Zhang T, Zhou X, Li H, et al. A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients. Mol Biosyst. 2014;10(8):2126–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Yin M, Zhao F, Lou G, Zhang H, Sun M, Li C, et al. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer. Int J Gynecol Cancer. 2011;21(1):92–9.PubMedGoogle Scholar
  13. 13.
    Yin M, Zhang H, Li H, Li X, Liu Y, Chen X, et al. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. J Surg Oncol. 2012;105(2):206–11.CrossRefPubMedGoogle Scholar
  14. 14.
    Rob L, Halaska M, Robova H. Nerve-sparing and individually tailored surgery for cervical cancer. Lancet Oncol. 2010;11(3):292–301. Review.CrossRefPubMedGoogle Scholar
  15. 15.
    Lin HM, Barnett MP, Roy NC, Joyce NI, Zhu S, Armstrong K, et al. Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn’s disease. J Proteome Res. 2010;9(4):1965–75.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang J, Yan L, Chen W, Lin L, Song X, Yan X, et al. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal Chim Acta. 2009;650(1):16–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.CrossRefPubMedGoogle Scholar
  18. 18.
    Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009;37:603–10.CrossRefGoogle Scholar
  19. 19.
    Smith CA, Maille OG, Want EJ, Qin C, Trauger SA, Brandon TR, et al. METLIN: a metabolite mass spectral database. Ther Drug Monit. 2005;27:747–51.CrossRefPubMedGoogle Scholar
  20. 20.
    Kjaer S, Hodall E, Frederiksen K, Munk C, van den Brule A, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66(21):10630–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Asaoka Y, Yoshida K, Sasaki Y, Nishizuka Y. Potential role of phospholipase A2 in HL-60 cell differentiation to macrophages induced by protein kinase C activation. Proc nat Acad Sci (Wash). 1993;90:4917–21.CrossRefGoogle Scholar
  22. 22.
    Yoshida K, Asaoka Y, Nishizuka Y. Platelet activation by simultaneous actions of diacylglycerol and unsaturated fatty acids. Proc nat Acad Sci (Wash). 1992;89:6443–6.CrossRefGoogle Scholar
  23. 23.
    Podo F. Tumour phospholipid metabolism. Review article. NMR Biomed. 1999;12:413–39.CrossRefPubMedGoogle Scholar
  24. 24.
    Podo F, Sardanelli F, Iorio E, Canese R, Carpinelli G, Alfonso F. Abnormal choline phospholipid metabolism in breast and ovary cancer: molecular bases for noninvasive imaging approaches. Curr Mol Imag Rev. 2007;3:123–37.CrossRefGoogle Scholar
  25. 25.
    Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61:3599–603.PubMedGoogle Scholar
  26. 26.
    Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D’Ascenzo S, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65:9369–76.CrossRefPubMedGoogle Scholar
  27. 27.
    Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm. 2006;3:496–506.CrossRefPubMedGoogle Scholar
  28. 28.
    Lunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics. 2006;7:1109–23.CrossRefGoogle Scholar
  29. 29.
    Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer. 1997;71(1):31–4.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.State Key Laboratory of Natural Products, Jiangsu Key Laboratory of TCM Evaluation and Translational Research Department of Complex Prescription of TCMChina Pharmaceutical UniversityNanjingChina
  2. 2.Department of Gynecology OncologyThe Tumor Affiliated Hospital of Harbin Medical UniversityHarbinChina
  3. 3.Department of PathologyYale School of MedicineNew HavenUSA
  4. 4.Department of Epidemiology and BiostatisticsHarbin Medical UniversityHarbinChina

Personalised recommendations